Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
In development
Reference number: GID-TA10745
Expected publication date:
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation.
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in late August 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late October 2023.